Cargando…

Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis

BACKGROUND: Acute kidney injury (AKI) after surgery is associated with increased mortality and healthcare costs. Fenoldopam is a selective dopamine-1 receptor agonist with renoprotective properties. We conducted a systematic review and meta-analysis of randomised controlled trials comparing fenoldop...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillies, Michael A., Kakar, Vivek, Parker, Robert J., Honoré, Patrick M., Ostermann, Marlies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699343/
https://www.ncbi.nlm.nih.gov/pubmed/26703329
http://dx.doi.org/10.1186/s13054-015-1166-4
_version_ 1782408172390055936
author Gillies, Michael A.
Kakar, Vivek
Parker, Robert J.
Honoré, Patrick M.
Ostermann, Marlies
author_facet Gillies, Michael A.
Kakar, Vivek
Parker, Robert J.
Honoré, Patrick M.
Ostermann, Marlies
author_sort Gillies, Michael A.
collection PubMed
description BACKGROUND: Acute kidney injury (AKI) after surgery is associated with increased mortality and healthcare costs. Fenoldopam is a selective dopamine-1 receptor agonist with renoprotective properties. We conducted a systematic review and meta-analysis of randomised controlled trials comparing fenoldopam with placebo to prevent AKI after major surgery. METHODS: We searched EMBASE, PubMed, meta-Register of randomised controlled trials and Cochrane CENTRAL databases for trials comparing fenoldopam with placebo in patients undergoing major surgery. The primary outcome was incidence of new AKI. Secondary outcomes were requirement for renal replacement therapy and hospital mortality. RESULTS: Eighty-three publications were screened; 23 studies underwent full data extraction and scoring. Six trials were suitable for inclusion in the data synthesis (total of 507 subjects undergoing cardiovascular surgery, partial nephrectomy, liver transplant surgery). Five studies were rated at high risk of bias. Data on post-operative incidence of AKI were available in five of the six trials (total of 471 patients) but definitions of AKI varied between studies. Of the 238 patients receiving fenoldopam, 45 (18.9 %) developed AKI compared to 62 (26.6 %) of the 233 patients who received placebo (p = 0.004, I(2) = 0 %; random-effects model odds ratio 0.46, 95 % confidence interval 0.27–0.79). In patients treated with fenoldopam, there was no difference in renal replacement therapy (n = 478; p = 0.11, I(2) = 47 %; fixed-effect model odds ratio 0.27, 95 % confidence interval 0.06–1.19) or hospital mortality (p = 0.60, I(2) = 0 %; fixed-effect model odds ratio 1.0, 95 % confidence interval 0.14–7.37). CONCLUSIONS: In this analysis, peri-operative treatment with fenoldopam was associated with a significant reduction in post-operative AKI but it had no impact on renal replacement therapy or hospital mortality. Equipoise remains for further large trials in this area since the studies were conducted in three types of surgery, the majority of studies were rated at high risk of bias and the criteria for AKI varied between trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-1166-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4699343
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46993432016-01-05 Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis Gillies, Michael A. Kakar, Vivek Parker, Robert J. Honoré, Patrick M. Ostermann, Marlies Crit Care Research BACKGROUND: Acute kidney injury (AKI) after surgery is associated with increased mortality and healthcare costs. Fenoldopam is a selective dopamine-1 receptor agonist with renoprotective properties. We conducted a systematic review and meta-analysis of randomised controlled trials comparing fenoldopam with placebo to prevent AKI after major surgery. METHODS: We searched EMBASE, PubMed, meta-Register of randomised controlled trials and Cochrane CENTRAL databases for trials comparing fenoldopam with placebo in patients undergoing major surgery. The primary outcome was incidence of new AKI. Secondary outcomes were requirement for renal replacement therapy and hospital mortality. RESULTS: Eighty-three publications were screened; 23 studies underwent full data extraction and scoring. Six trials were suitable for inclusion in the data synthesis (total of 507 subjects undergoing cardiovascular surgery, partial nephrectomy, liver transplant surgery). Five studies were rated at high risk of bias. Data on post-operative incidence of AKI were available in five of the six trials (total of 471 patients) but definitions of AKI varied between studies. Of the 238 patients receiving fenoldopam, 45 (18.9 %) developed AKI compared to 62 (26.6 %) of the 233 patients who received placebo (p = 0.004, I(2) = 0 %; random-effects model odds ratio 0.46, 95 % confidence interval 0.27–0.79). In patients treated with fenoldopam, there was no difference in renal replacement therapy (n = 478; p = 0.11, I(2) = 47 %; fixed-effect model odds ratio 0.27, 95 % confidence interval 0.06–1.19) or hospital mortality (p = 0.60, I(2) = 0 %; fixed-effect model odds ratio 1.0, 95 % confidence interval 0.14–7.37). CONCLUSIONS: In this analysis, peri-operative treatment with fenoldopam was associated with a significant reduction in post-operative AKI but it had no impact on renal replacement therapy or hospital mortality. Equipoise remains for further large trials in this area since the studies were conducted in three types of surgery, the majority of studies were rated at high risk of bias and the criteria for AKI varied between trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-1166-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-25 2015 /pmc/articles/PMC4699343/ /pubmed/26703329 http://dx.doi.org/10.1186/s13054-015-1166-4 Text en © Gillies et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gillies, Michael A.
Kakar, Vivek
Parker, Robert J.
Honoré, Patrick M.
Ostermann, Marlies
Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
title Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
title_full Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
title_fullStr Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
title_full_unstemmed Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
title_short Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
title_sort fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699343/
https://www.ncbi.nlm.nih.gov/pubmed/26703329
http://dx.doi.org/10.1186/s13054-015-1166-4
work_keys_str_mv AT gilliesmichaela fenoldopamtopreventacutekidneyinjuryaftermajorsurgeryasystematicreviewandmetaanalysis
AT kakarvivek fenoldopamtopreventacutekidneyinjuryaftermajorsurgeryasystematicreviewandmetaanalysis
AT parkerrobertj fenoldopamtopreventacutekidneyinjuryaftermajorsurgeryasystematicreviewandmetaanalysis
AT honorepatrickm fenoldopamtopreventacutekidneyinjuryaftermajorsurgeryasystematicreviewandmetaanalysis
AT ostermannmarlies fenoldopamtopreventacutekidneyinjuryaftermajorsurgeryasystematicreviewandmetaanalysis